Articles

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Dept of Hematology, Amsterdam UMC, University of Amsterdam, and LYMMCARE, Amsterdam, The Netherlands;
Dept of Hematology, Amsterdam UMC, University of Amsterdam, and LYMMCARE, Amsterdam, The Netherlands;
Dept of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
Dept of Hematology, University of Groningen, UMC Groningen, Groningen, The Netherlands;
Dept of Hematology, Centre Hospitalier Universitaire, Lille, France;
Dept of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
Dept of Hematology, Hopital Saint Louis, Paris, France;
Dept of Hematology, Rigshospitalet, Copenhagen, Denmark;
Dept of Hematology, Centre Hospitalier Universitaire, Nantes, France;
Dept of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;
Dept of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
Dept of Hematology, University of Groningen, UMC Groningen, Groningen, The Netherlands;
Dept of Hematology, Amsterdam UMC, University of Amsterdam, and LYMMCARE, Amsterdam, The Netherlands;
Dept of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, The Netherlands;
Dept of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
Dept of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands;
Dept of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands;
Dept. of Pathology and Medical Biology, UMC Groningen, University of Groningen, the Netherlands;
Dept of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Dept of Hematology, Amsterdam UMC, University of Amsterdam, and LYMMCARE, Amsterdam, The Netherlands;
Haematologica Early view Apr 9, 2020 https://doi.org/10.3324/haematol.2019.243238